Showing 13,581 - 13,600 results of 49,729 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((point decrease) OR (mean decrease)) ))', query time: 1.31s Refine Results
  1. 13581
  2. 13582
  3. 13583

    Directed evolution of HIV-1 to utilize CD4<sup>low</sup> target cells. by David Beauparlant (3491435)

    Published 2017
    “…<b>(E)</b> Adaptation to CD4<sup>low</sup> target cells results in high resistance to CD4 inhibitor compared to wild type HIV-1 isolates. Comparison of IC50 of CD4-blocking DARPin 55.2 against 41 wild-type HIV-1 strains from different clades (black dots, see <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1006255#ppat.1006255.s003" target="_blank">S3 Table</a> for details on virus panel and individual IC50 values) and the CD4<sup>low</sup> adaptation virus panel (colored dots, see legend) probed by Env pseudovirus infection on TZM-bl cells. …”
  4. 13584
  5. 13585
  6. 13586
  7. 13587
  8. 13588
  9. 13589

    Dysregulated alternative splicing in DM1 hiNeurons at 10 DPI. by Mougina K. Eltahir (12988153)

    Published 2022
    “…(d) Scatter plots pertaining to Fig 5c show decreased inclusion of <i>MAPT</i> e2 (top), <i>CSNK1D</i> e9 (bottom left) and <i>MPRIP</i> e9 (bottom right) in DM1 hiNeurons. …”
  10. 13590
  11. 13591

    Phenotypic characterization of <i>CsIVP</i>-RNAi transgenic plants. by Shuangshuang Yan (798064)

    Published 2020
    “…<p>(A) Plant morphology of WT and <i>CsIVP-</i>RNAi lines R5, R3, and R2. …”
  12. 13592
  13. 13593
  14. 13594
  15. 13595
  16. 13596

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
  17. 13597

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
  18. 13598

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
  19. 13599

    Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multip... by Obdulia Rabal (124515)

    Published 2021
    “…The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising <i>in vitro</i> activity of <b>12a</b> (CM-444) with GI<sub>50</sub> of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. …”
  20. 13600